Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Calvert

Showing results (151-160 of 220) with videos related to

Pageof 22
Sort By:
Cancer Treatment Reports|August 1, 1986
Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouseD R Newell, D L Alison, A H Calvert, et al.
British Journal of Cancer|January 7, 2010
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapyJ E Nutt, A R A Razak, K O'Toole, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade gliomaM Bower, E S Newlands, N M Bleehen, et al.
Journal of Medicinal Chemistry|March 1, 1989
Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 positionP R Marsham, P Chambers, A J Hayter, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancerM Gore, A Oza, G Rustin, et al.
British Journal of Cancer|May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxelA N Hughes, M J Griffin, D R Newell, et al.
Biochemical Pharmacology|October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)A L Jackman, D R Newell, W Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activityP G Smith, H D Thomas, H C Barlow, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2003
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trialsG Atalay, L Biganzoli, F Renard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.
Pageof 22

Showing results (151-160 of 220) with videos related to

Sort By:
Pageof 22
Cancer Treatment Reports|August 1, 1986
Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouseD R Newell, D L Alison, A H Calvert, et al.
British Journal of Cancer|January 7, 2010
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapyJ E Nutt, A R A Razak, K O'Toole, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade gliomaM Bower, E S Newlands, N M Bleehen, et al.
Journal of Medicinal Chemistry|March 1, 1989
Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 positionP R Marsham, P Chambers, A J Hayter, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancerM Gore, A Oza, G Rustin, et al.
British Journal of Cancer|May 2, 2000
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxelA N Hughes, M J Griffin, D R Newell, et al.
Biochemical Pharmacology|October 24, 1991
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)A L Jackman, D R Newell, W Gibson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activityP G Smith, H D Thomas, H C Barlow, et al.
European Journal of Cancer (Oxford, England : 1990)|November 7, 2003
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trialsG Atalay, L Biganzoli, F Renard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 daysA N Hughes, I Rafi, M J Griffin, et al.
Pageof 22